aTyr Pharma Company Profile (NASDAQ:LIFE)

About aTyr Pharma

aTyr Pharma logoaTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NASDAQ
  • Symbol: LIFE
  • CUSIP: 53217V10
Key Metrics:
  • Previous Close: $3.38
  • 50 Day Moving Average: $3.117
  • 200 Day Moving Average: $3.034
  • 52-Week Range: $23,718,000.00 - $2.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.34
  • P/E Growth: 0.000
  • Market Cap: $80.05M
  • Outstanding Shares: 23,718,000
  • Beta: 3.52
Profitability:
  • Return on Equity: -65.72%
  • Return on Assets: -57.31%
Debt:
  • Current Ratio: 6.17%
  • Quick Ratio: 6.17%
Additional Links:
Companies Related to aTyr Pharma:

Analyst Ratings

Consensus Ratings for aTyr Pharma (NASDAQ:LIFE) (?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.62 (7.16% upside)

Analysts' Ratings History for aTyr Pharma (NASDAQ:LIFE)
Show:
DateFirmActionRatingPrice TargetDetails
12/15/2016BMO Capital MarketsReiterated RatingMarket Perform$8.00 -> $4.00View Rating Details
12/13/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$2.85View Rating Details
8/16/2016Citigroup Inc.Boost Price TargetNeutral$3.00 -> $4.00View Rating Details
3/31/2016William BlairDowngradeOutperform -> Market PerformView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for aTyr Pharma (NASDAQ:LIFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2017        
11/14/2016Q3 2016($0.67)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.71)($0.65)ViewN/AView Earnings Details
5/11/2016Q1($0.70)($0.68)ViewN/AView Earnings Details
3/30/2016Q4($0.52)($0.70)ViewN/AView Earnings Details
11/10/2015Q3($0.48)($0.48)ViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.74)ViewN/AView Earnings Details
6/18/2015Q115($0.41)($9.39)ViewN/AView Earnings Details
11/5/2013Q313$0.97$1.02$926.10 million$936.00 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.96$0.72$952.06 million$944.00 millionViewN/AView Earnings Details
5/2/2013Q1 2013$1.04$1.07$958.56 million$963.00 millionViewN/AView Earnings Details
2/4/2013Q4 2012$1.11$1.11$988.85 million$998.90 millionViewN/AView Earnings Details
11/1/2012Q312$0.89$0.92$907.91 million$911.00 millionViewN/AView Earnings Details
7/31/2012$0.97$0.96ViewN/AView Earnings Details
2/7/2012$1.04$1.06ViewN/AView Earnings Details
10/25/2011$0.88$0.94ViewN/AView Earnings Details
7/28/2011$0.95$0.89ViewN/AView Earnings Details
4/26/2011$0.85$0.85ViewN/AView Earnings Details
2/3/2011$0.87$0.90ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)
Current Year EPS Consensus Estimate: $-2.550 EPS
Next Year EPS Consensus Estimate: $-2.520 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.70)($0.70)($0.70)
Q2 20161($0.68)($0.68)($0.68)
Q3 20161($0.66)($0.66)($0.66)
Q4 20161($0.61)($0.61)($0.61)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for aTyr Pharma (NASDAQ:LIFE)
Insider Ownership Percentage: 28.90%
Institutional Ownership Percentage: 44.84%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/21/2016Paul SchimmelDirectorBuy25,000$2.28$57,000.00View SEC Filing  
12/20/2016Ashraf AmanullahVPBuy11,000$2.25$24,750.00View SEC Filing  
12/19/2016John MendleinCEOBuy69,000$2.20$151,800.00View SEC Filing  
12/16/2016Paul SchimmelDirectorBuy50,000$2.48$124,000.00View SEC Filing  
5/11/2016Grove MatsuokaInsiderBuy12,412$3.04$37,732.48View SEC Filing  
4/14/2016Paul SchimmelDirectorBuy66,219$4.18$276,795.42View SEC Filing  
4/13/2016Paul SchimmelDirectorBuy9,835$3.85$37,864.75View SEC Filing  
4/12/2016Paul SchimmelDirectorBuy9,127$3.71$33,861.17View SEC Filing  
4/11/2016Paul SchimmelDirectorBuy32,659$3.57$116,592.63View SEC Filing  
4/8/2016Paul SchimmelDirectorBuy85,000$3.22$273,700.00View SEC Filing  
4/7/2016Paul SchimmelDirectorBuy40,000$3.19$127,600.00View SEC Filing  
4/6/2016Paul SchimmelDirectorBuy25,000$3.20$80,000.00View SEC Filing  
4/5/2016John MendleinCEOBuy2,500$3.55$8,875.00View SEC Filing  
4/5/2016Paul SchimmelDirectorBuy25,000$3.52$88,000.00View SEC Filing  
5/12/2015James E FlynnInsiderBuy50,000$14.00$700,000.00View SEC Filing  
5/12/2015Sofinnova Venture Partners Ix,Major ShareholderBuy320,000$14.00$4,480,000.00View SEC Filing  
5/29/2013David C UprichardDirectorSell2,010$74.04$148,820.40View SEC Filing  
5/28/2013John A CottinghamInsiderSell60,000$74.03$4,441,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
DateHeadline
finance.yahoo.com logoHigh court ruling limits international reach of patent laws (NASDAQ:LIFE)
finance.yahoo.com - February 22 at 6:26 PM
News IconAnalyst Predictions Are In For aTyr Pharma, Inc. (NASDAQ:LIFE) Endeavour Silver Corp. (NYSE:EXK) - Sherwood Daily (NASDAQ:LIFE)
sherwooddaily.com - February 14 at 7:45 PM
News IconDo Analysts See Any Upside to aTyr Pharma Inc (NASDAQ:LIFE) Shares? - Rockville Register (NASDAQ:LIFE)
rockvilleregister.com - February 14 at 7:45 PM
News IconEarnings Reaction History: aTyr Pharma, Inc. (LIFE) Post Earnings Price Moves - Post Analyst (NASDAQ:LIFE)
postanalyst.com - February 14 at 12:27 AM
News IconaTyr Pharma Inc LIFE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:LIFE)
www.bioportfolio.com - February 1 at 7:07 PM
News IconVolatility Watch on Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) - The Tribune (NASDAQ:LIFE)
lakecitytribune.com - February 1 at 5:08 AM
News IconStock Seesawing as Volatility Sweeps in on aTyr Pharma, Inc. (NASDAQ:LIFE) - Wall Street Beacon (NASDAQ:LIFE)
wsbeacon.com - January 26 at 3:17 PM
News IconChecking the Piotroski Score on Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) - The Tribune (NASDAQ:LIFE)
lakecitytribune.com - January 25 at 12:00 AM
News IconaTyr Pharma Inc (NASDAQ:LIFE) Jumps Higher on Fast Track ... - The Oracle Dispatch (NASDAQ:LIFE)
oracledispatch.com - January 22 at 6:05 PM
investopedia.com logoAtyr Pharma Spikes 33% on FDA Update (LIFE) (NASDAQ:LIFE)
www.investopedia.com - January 20 at 1:06 AM
investopedia.com logoAtyr Pharma Stock Spikes 33% on FDA Updates (NASDAQ:LIFE)
www.investopedia.com - January 19 at 8:04 PM
News IconStock Update on Earnings & Estimates for aTyr Pharma Inc (NASDAQ:LIFE) - Aiken Advocate (NASDAQ:LIFE)
aikenadvocate.com - January 19 at 4:52 AM
News IconShooting From the Hip, Stock Reaches Most Volatile List: aTyr Pharma, Inc. (NASDAQ:LIFE) - Wall Street Beacon (NASDAQ:LIFE)
wsbeacon.com - January 19 at 4:52 AM
News IconCan This Stock Gain Any Traction: aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - January 19 at 4:52 AM
News IconCutting the Mustard Mid-Session: aTyr Pharma, Inc. (NASDAQ:LIFE) - Wall Street Beacon (NASDAQ:LIFE)
wsbeacon.com - January 19 at 4:52 AM
streetinsider.com logoaTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status - StreetInsider.com (NASDAQ:LIFE)
www.streetinsider.com - January 19 at 4:52 AM
News IconInteresting, Mixed Session (NASDAQ:LIFE)
www.fxstreet.com - January 18 at 11:50 PM
finanznachrichten.de logoGainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC... (NASDAQ:LIFE)
www.finanznachrichten.de - January 18 at 11:50 PM
4-traders.com logoNetworkNewsBreaks – aTyr’s (NASDAQ: LIFE) Resolaris™ Obtains Fast Track Designation from FDA, Partial Clinical Hold Removed (NASDAQ:LIFE)
www.4-traders.com - January 18 at 6:49 PM
streetinsider.com logoaTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status (NASDAQ:LIFE)
www.streetinsider.com - January 18 at 6:49 PM
us.rd.yahoo.com logoFDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris (NASDAQ:LIFE)
us.rd.yahoo.com - January 18 at 6:49 PM
News IconA Keen Look at These Shares: aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - January 13 at 7:31 PM
News IconKnuckling Down on Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - January 11 at 12:09 AM
sg.finance.yahoo.com logoRoberts recuses from patent case after discovering conflict (NASDAQ:LIFE)
sg.finance.yahoo.com - January 4 at 7:08 PM
News IconCan This Stock Pick Up Any Momentum: aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - December 28 at 6:10 PM
marketexclusive.com logoInsider Trading Activity Atyr Pharma Inc. (NASDAQ:LIFE) – VP Bought 11,000 shares of Stock (NASDAQ:LIFE)
marketexclusive.com - December 22 at 6:32 PM
finance.yahoo.com logoAtyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares (NASDAQ:LIFE)
finance.yahoo.com - December 21 at 7:06 PM
News IconBargain Hunters Should Take a Look at aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - December 21 at 7:01 AM
News IconEtching Out Gains Pre-Bell, Shares Pick Up Momentum: aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - December 20 at 11:54 AM
kcregister.com logoBanner Corporation (NASDAQ:BANR) Declares Quarterly Cash Dividend of $0.23 Per Share (NASDAQ:LIFE)
www.kcregister.com - December 19 at 10:47 AM
News IconStock Ballooning Up Pre-Bell: aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - December 17 at 11:40 PM
insidermonkey.com logoDoes aTyr Pharma Inc (LIFE) Stack Up Against Its Peers? - Insider Monkey (blog) (NASDAQ:LIFE)
www.insidermonkey.com - December 17 at 11:40 PM
News IconDoes aTyr Pharma Inc (LIFE) Stack Up Against Its Peers? (NASDAQ:LIFE)
feedproxy.google.com - December 16 at 10:15 PM
News IconShares Ticking Lower in Trade: aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - December 13 at 11:44 PM
marketexclusive.com logoATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:LIFE)
marketexclusive.com - December 13 at 6:43 PM
finance.yahoo.com logoaTyr Pharma Drops on Clinical Update (NASDAQ:LIFE)
finance.yahoo.com - December 13 at 6:43 PM
finance.yahoo.com logoaTyr Pharma downgraded by JP Morgan (NASDAQ:LIFE)
finance.yahoo.com - December 13 at 6:43 PM
us.rd.yahoo.com logo7:00 am aTyr Pharma announces clinical results from exploratory trials assessing the safety and potential activity of Resolaris: aTyr believes that these results are supportive of the advancement of Resolaris as a single treatment for vario (NASDAQ:LIFE)
us.rd.yahoo.com - December 13 at 9:56 AM
finance.yahoo.com logoaTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris™ in Exploratory Trials (NASDAQ:LIFE)
finance.yahoo.com - December 13 at 9:56 AM
biz.yahoo.com logoATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events (NASDAQ:LIFE)
biz.yahoo.com - December 13 at 9:56 AM
finance.yahoo.com logoaTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference (NASDAQ:LIFE)
finance.yahoo.com - December 9 at 9:31 AM
investingnews.com logoOhr Pharmaceutical Announces Pricing of $7.75 Million Public Offering of Common Stock and Warrants (NASDAQ:LIFE)
investingnews.com - December 8 at 6:52 PM
finance.yahoo.com logoAllergan Comments on PTAB Decision Regarding Mylan's Petitions for Inter Partes Review (IPR) of RESTASIS® Patents (NASDAQ:LIFE)
finance.yahoo.com - December 8 at 6:52 PM
News IconGlobal Animal Pharmaceuticals Market is Driven by Increasing Zoonotic and Food Borne Diseases (NASDAQ:LIFE)
www.abnewswire.com - December 8 at 6:52 PM
smarteranalyst.com logoCompany Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Announces Phase 3 Results For Psoriasis Treatment IDP-118 (NASDAQ:LIFE)
www.smarteranalyst.com - December 8 at 6:52 PM
News IconRising price of opioid OD antidote could cost lives (NASDAQ:LIFE)
www.cbsnews.com - December 8 at 6:52 PM
News IconStock Popping Higher Pre-Market: aTyr Pharma, Inc. (NASDAQ:LIFE) - Prospect Journal (NASDAQ:LIFE)
prospectjournal.com - December 7 at 3:37 PM
capitalcube.com logoaTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 (NASDAQ:LIFE)
www.capitalcube.com - December 5 at 6:28 PM
News IconaTyr Pharma, Inc. LIFE Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:LIFE)
www.bioportfolio.com - November 24 at 9:06 AM
finance.yahoo.com logoATYR PHARMA INC Financials (NASDAQ:LIFE)
finance.yahoo.com - November 23 at 5:58 PM

Social

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?

4 brokerages have issued twelve-month price targets for aTyr Pharma's stock. Their forecasts range from $2.85 to $4.00. On average, they anticipate aTyr Pharma's share price to reach $3.62 in the next year.

When will aTyr Pharma announce their earnings?

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.

Who owns aTyr Pharma stock?

aTyr Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Alyeska Investment Group L.P. (4.52%), EcoR1 Capital LLC (4.12%) and Dimensional Fund Advisors LP (0.23%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, James E Flynn, John Mendlein, Paul Schimmel and Sofinnova Venture Partners Ix,.

Who bought aTyr Pharma stock? Who is buying aTyr Pharma stock?

aTyr Pharma's stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC and Alyeska Investment Group L.P.. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, James E Flynn, John Mendlein, Paul Schimmel and Sofinnova Venture Partners Ix,.

How do I buy aTyr Pharma stock?

Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of aTyr Pharma stock cost?

One share of aTyr Pharma stock can currently be purchased for approximately $3.38.

aTyr Pharma (NASDAQ:LIFE) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for aTyr Pharma (NASDAQ:LIFE)

Earnings History Chart

Earnings by Quarter for aTyr Pharma (NASDAQ:LIFE)

Dividend History Chart

Dividend Payments by Quarter for aTyr Pharma (NASDAQ:LIFE)

Last Updated on 2/27/2017 by MarketBeat.com Staff